论文部分内容阅读
目的探索Ａ型肉毒毒素（ＢＴＸＡ）在神经肌肉疾病中的治疗应用，证实和比较国产ＢＴＸＡ（ＣＢＴＸＡ）与美国产ＢＴＸＡ（ｂｏｔｏｘ）治疗局限性肌张力障碍和肌肉痉挛等的疗效和不良反应。方法４年间用ｂｏｔｏｘ和ＣＢＴＸＡ分别注射治疗１９２和５９３例局限性肌张力障碍和肌肉痉挛等运动障碍性疾病，共计７８５例，注射１３９３次。随访３～４８个月，分析前瞻性、开放性临床研究的结果。结果ｂｏｔｏｘ或ＣＢＴＸＡ的疗效没有明显差别，症状完全缓解占３０．４％，明显改善占５７．８％，部分改善８．９％，无效１．４％（１１例资料不全）。疗效平均持续约３～５个月。最引人关注的并发症是眼睑下垂和吞咽困难，一般程度不重，约数周内自行好转。ｂｏｔｏｘ与ＣＢＴＸＡ治疗的反应潜伏期、疗效持续时间、综合治疗和患者的主观改善差异均无显著性意义，但治疗达到相似疗效所需ＣＢＴＸＡ的剂量较大，且ＣＢＴＸＡ组有５例注射后数天内出现皮疹，其余不良反应两组之间差异无显著性意义。绝大多数患者需重复注射维持疗效。肌肉痉挛复发多为部分复发，重复注射的疗效没有下降，反应潜伏期和疗效持续时间保持不变，所用剂量也相对稳定或略有减小。结论局部注射ｂｏｔｏｘ或ＣＢＴ?
Objective To explore the therapeutic application of botulinum toxin type A (BTXA) in neuromuscular diseases and to confirm and compare the limitations of domestic BTXA (CBTXA) and BTXA (botox) in the treatment of dystonia and muscle Spasms and other effects and adverse reactions. Methods A total of 785 cases were injected with botox and CBTXA for 192 and 593 cases of dystonia and muscle spasm, respectively, for a total of 793 injections. Follow up for 3 ~ 48 months, the results of prospective, open clinical studies were analyzed. Results The efficacy of botox or CBTXA was not significantly different. The symptoms were completely relieved (30.4%), marked improvement (57.8%), partial improvement (8.9%) and ineffectiveness (1.4%). The average duration of about 3 to 5 months. The most interesting complication is ptosis and dysphagia, which is generally not severe and improves on the order of a few weeks. There was no significant difference between the response time of botox and CBTXA, the duration of curative effect, the comprehensive treatment and the subjective improvement of patients. However, the dose of CBTXA needed for the treatment to achieve similar curative effect was larger, and the dose of CBTXA was 5 Cases within a few days after injection rash appeared, the remaining adverse reactions no significant difference between the two groups. The vast majority of patients need repeated injections to maintain efficacy. Recurrence of muscle spasm and more for the part of relapse, the efficacy of repeated injections did not decline, the response latency and efficacy duration remained unchanged, the dose used is relatively stable or slightly reduced. Conclusion Injection of botox or CBT locally?